Innovation Performance Of Overseas Technology Acquisition Model Of Chinese Pharmaceutical Enterprises

The pharmaceutical manufacturing industry is related to the national economy and life.It is a basic and strategic industry of the country,as well as a high-tech industry.Its core competitiveness is technological innovation with new drug research and development as the core.However,compared with the mature medical research and development system in developed countries,China’s pharmaceutical industry is currently facing a difficult situation,such as weak basic research,insufficient research and development investment,the flood of generic drugs,and the scarcity of innovative drug research and development.Since the implementation of the New Deal in 2009,under the guidance of the current import substitution strategy in the pharmaceutical industry,and in the face of the globalization trend of enterprise innovation network,improving their own technological innovation ability will be the key for Chinese pharmaceutical enterprises to build sustainable competitive advantages.Therefore,part of China’s big drug firms began to take the initiative to "go out",to obtain overseas technical resources,enterprise development pattern began to present a externalized,multinational,platform,etc.,to multinational technology,for the purpose of investment by setting up the overseas research and development center and overseas R&D cooperation and the technology of overseas m&a,set up foreign technology acquisition mode,has become a local drug firms access to external innovation resources in our country,realize the important source of technological innovation.In this paper,according to the analysis method of "motivation-patterns-performance",first of all,the mode of Chinese drug companies overseas technology for analysis,according to the enterprise research and development of external motivation,according to the enterprise considering the time cost,and different expectations,and innovation for the future returns to Chinese drug companies overseas technology the type of access to overseas mergers and acquisitions,overseas R&D cooperation and set up overseas R&D center three main modes.Secondly,based on the resource idea based on the basic theory and enterprise innovation network theory,draw lessons from the latest achievements in the theory of industrial organization,three levels in the patent,technology and knowledge,analyzes the three kinds of typical Chinese drug companies overseas technology acquisition mode in the process of the impact on the enterprise innovation performance,enterprise shown on the patent incentives,competition,the effect of "efficiency" and "substitution effect" and "can account for sexual effect" of patent protection,as well as the technical knowledge and management knowledge of "spillover effect".Finally,based on the overseas technology investment events of Listed pharmaceutical companies in Shanghai and Shenzhen,a panel structure database is constructed by empirical analysis and relevant hypotheses are proposed.A random effect model is established by using multiple linear regression method to verify the relevant hypotheses in this paper.The research in this paper is problem-oriented,and the research results not only provide useful ideas for Chinese pharmaceutical companies to make strategic choices in overseas technology acquisition,but also provide references for the cultivation of national industrial innovation ability and the formulation of relevant policies.In this paper,the results show that:(1)the present overseas technology of Chinese pharmaceutical enterprise investment behavior,is based on patent strategic resources of knowledge,technology and seeking behavior,because in the process of enterprise’s patent competition,"efficiency effect" more than "substitution effect",therefore,the enterprise innovation performance has a significant role in promoting;(2)Compared with the mode of overseas R&D cooperation and the mode of setting up overseas R&D centers,the mode of overseas technology merger and acquisition has a more significant impact on the innovation performance of enterprises,which reflects the higher innovation incentive return of enterprises.(3)In addition,we find that the R&D intensity of pharmaceutical enterprises has a certain influence on the output efficiency of technological innovation(namely,patent conversion rate).The R&D intensity of pharmaceutical enterprises reflects the relative strength and technological innovation willingness of enterprises on the one hand,and the transformation efficiency of their innovation achievements on the other hand.The research of this paper finds that in the relationship between the two modes of overseas R&D cooperation and the establishment of overseas R&D center and innovation performance,the internal R&D intensity plays a certain regulating role,while it does not play a role in the breakthrough mode.